Detection of residual pluripotent stem cells in cell therapy products utilizing droplet digital PCR: an international multisite evaluation study
Authors:
Open Access
- 9 August 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (10) , 1001-1014
Abstract
The presence of residual undifferentiated pluripotent stem cells (PSCs) in PSC-derived cell therapy products (CTPs) is a major safety issue for their clinical application, due to the potential risk of PSC-derived tumor formation. An international multidisciplinary multisite study to evaluate a droplet digital PCR (ddPCR) approach to detect residual undifferentiated PSCs in PSC-derived CTPs was conducted as part of the Health and Environmental Sciences Institute Cell Therapy-TRAcking, Circulation & Safety Technical Committee. To evaluate the use of ddPCR in quantifying residual iPSCs in a cell sample, different quantities of induced pluripotent stem cells (iPSCs) were spiked into a background of iPSC-derived cardiomyocytes (CMs) to mimic different concentrations of residual iPSCs. A one step reverse transcription ddPCR (RT-ddPCR) was performed to measure mRNA levels of several iPSC-specific markers and to evaluate the assay performance (precision, sensitivity, and specificity) between and within laboratories. The RT-ddPCR assay variability was initially assessed by measuring the same RNA samples across all participating facilities. Subsequently, each facility independently conducted the entire process, incorporating the spiking step, to discern the parameters influencing potential variability. Our results show that a RT-ddPCR assay targeting ESRG, LINC00678, and LIN28A genes offers a highly sensitive and robust detection of impurities of iPSC-derived CMs and that the main contribution to variability between laboratories is the iPSC-spiking procedure, and not the RT-ddPCR. The RT-ddPCR assay would be generally applicable for tumorigenicity evaluation of PSC-derived CTPs with appropriate marker genes suitable for each CTP.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP20mk0104176, JP20mk0104177, JP22bk0104157)
This publication has 28 references indexed in Scilit:
- Country-specific regulation and international standardization of cell-based therapeutic products derived from pluripotent stem cellsStem Cell Reports, 2023
- Identification of marker genes to monitor residual iPSCs in iPSC-derived productsCytotherapy, 2022
- Highly Sensitive Detection of Human Pluripotent Stem Cells by Loop-Mediated Isothermal AmplificationStem Cell Reviews and Reports, 2022
- Tumorigenicity assessment of cell therapy products: The need for global consensus and points to considerCytotherapy, 2019
- Detection of small numbers of iPSCs in different heterogeneous cell mixtures with highly sensitive droplet digital PCRMolecular Biology Reports, 2019
- Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatmentJournal of Virological Methods, 2017
- Future Treatment of Heart Failure Using Human iPSC-Derived Cardiomyocytes2016
- Mapping Human Pluripotent-to-Cardiomyocyte Differentiation: Methylomes, Transcriptomes, and Exon DNA Methylation “Memories”EBioMedicine, 2016
- Highly sensitive droplet digital PCR method for detection of residual undifferentiated cells in cardiomyocytes derived from human pluripotent stem cellsRegenerative Therapy, 2015
- Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studiesStem Cell Research, 2009